Profil bibliographique

Dominique Berton-Rigaud

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

282Publications signalées

4129Citations signalées

2Affiliations récentes

Institutions déclarées

Institut de Cancérologie de Lorraine Institut de Cancérologie de l'Ouest

Domaines associés

Ovarian cancer diagnosis and treatmentUterine Myomas and TreatmentsEndometrial and Cervical Cancer TreatmentsPARP inhibition in cancer therapyRadiomics and Machine Learning in Medical Imaging

Publications récentes

Accès ouvert 2026 article

Prognostic impact of time to first recurrence in low-grade serous ovarian carcinoma: A multicentric retrospective study from the French TMRG network

Thomas MONTASSIER, Enora Laas, Judicaël Hotton, Dominique Berton-Rigaud et autres

0 citationsGynecologic Oncology

2026 article

Prognostic impact of time to first recurrence in low-grade serous ovarian carcinoma: a multicentric retrospective study from the french TMRG network

Thomas MONTASSIER, Enora LAAS, Anne‐Sophie Bats, Sébastien Gouy et autres

0 citationsInternational Journal of Gynecological Cancer

Accès ouvert 2025 article

Long-term quality of life in non-epithelial ovarian cancer survivors: TMRG-GINECO-Vivrovaire rare tumors case–control study

C. Dubot, Isabelle Ray‐Coquard, Justine Lequesne, Patricia Pautier et autres

1 citationBMC Medicine

2025 article

604MO Prognostic value of progression free status at 6 months on overall survival (OS) in platinum resistant ovarian cancer (PROC): Landmark analysis from the GCIG Symptom Benefit Study

Omali Pitiyarachchi, C. Lee, H-W. Sim, R. Oconnell et autres

0 citationsAnnals of Oncology

2025 article

1131P Upgrading the performance of ECOG performance status in recurrent ovarian cancer (ECOG+)

Omali Pitiyarachchi, H-W. Sim, Ryan P. O’Connell, Anne Lanceley et autres

0 citationsAnnals of Oncology

2025 article

NSGO-FANDANGO/ENGOT-EN1: A randomized phase II study of first-line combination chemotherapy with nintedanib/placebo in advanced/recurrent endometrial cancer

Kristina Lindemann, Dominique Berton-Rigaud, Jalid Sehouli, René dePont Christensen et autres

1 citationGynecologic Oncology

Accès ouvert 2025 article

69O Novel regimens for persistent/recurrent rare epithelial ovarian carcinomas (EOCs) selected according to biomarker status: ENGOT-GYN2/GOG-3051/BOUQUET phase II study results

Isabelle Laure Ray-Coquard, Robert F. Miller, Jubilee Brown, JW Kim et autres

3 citationsESMO Open

Accès ouvert 2025 article

Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Cancer (CHIPOR): A Randomized, Open-Label, Phase 3 Trial

Jean-Marc Classe, Pierre Méeus, Delphine Hudry, Romuald Wernert et autres

0 citationsObstetrical & Gynecological Survey

2025 conference-abstract

Abstract 5273: Changes in the tumor immune microenvironment during disease progression in gynecological carcinosarcoma: Exploratory analysis from the randomized ROCSAN GINECO trial

Sonia Canjura-Rodriguez, Victor Heurtier, Annalisa Pesavento, Justine Berthet et autres

0 citationsCancer Research

2025 article

Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial

Toon Van Gorp, Kathleen Moore, Gottfried E. Konecny, Alexandra Léary et autres

36 citationsThe Lancet Oncology

2025 article

Open Versus Closed HIPEC Techniques Following Cytoreductive Surgery In Epithelial Ovarian Cancer Comparison From The CHIPOR Randomized Trial

Naoual Bakrin, Olivier Gléhen, Pierre Meeus, Delphine Hudry et autres

0 citationsInternational Journal of Gynecological Cancer

2025 article

Surgical Outcomes In Low-Grade Serous Ovarian Cancer: Comparing Primary Debulking Surgery With Neoadjuvant Chemotherapy

Alexandra Madar, Judicaël Hotton, Anne‐Sophie Bats, Élodie Gauroy et autres

0 citationsInternational Journal of Gynecological Cancer

Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Métadonnées interrogées à la demande auprès de OpenAlex (CC0). Sources et limites.